Last updated May 16, 2026
Key finding
DPP-4 inhibitors appear safe for diabetic eye disease, showing no increased risk.
This review looked at whether DPP-4 inhibitors, a type of diabetes pill, affect the risk of diabetic eye disease. Researchers analyzed seven studies involving people with type 2 diabetes from several countries. The results showed no clear difference in eye disease risk between people taking DPP-4 inhibitors and those on other diabetes medications. This finding was consistent across different groups, though individual study results varied.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Systematic Review
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
DPP-4 inhibitors appear safe for diabetic eye disease, showing no increased risk.
Published in
Publication details and source links for this paper.
Wang M, Lu J, Dong J. Association between dipeptidyl peptidase-4 inhibitor use and diabetic retinopathy: a systematic review and meta-analysis of real-world studies. BMC Ophthalmol. 2024;24:272. doi:10.1186/s12886-024-03535-1
New diabetic eye disease → → (no clear change)
Worsening existing eye disease → → (no clear change)
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dipeptidyl peptidase-4 inhibitors and Diabetic retinopathy incidence.
This study contributes evidence to
Primary intervention
Dipeptidyl peptidase-4 inhibitors
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
1
Evidence pairs
16
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence topic
Save evidence
Intervention
Save evidence
Core evidence
The primary outcomes reported in this study.
Dipeptidyl peptidase-4 inhibitors → Diabetic retinopathy incidence
Dipeptidyl peptidase-4 inhibitors → Diabetic retinopathy incidence
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Adults with type 2 diabetes taking oral medications, especially those considering DPP-4 inhibitors
These were routine care studies, not controlled trials, so other differences between groups could affect results
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and Retinopathy.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
DPP-4 Inhibitors may improve Retinopathy.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Diabetic retinopathy incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | weak positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
